Literature DB >> 21219978

Development and application of a flow cytometric potency assay for DNA vaccines.

C V Badger1, J D Richardson, R L Dasilva, M J Richards, M D Josleyn, L C Dupuy, J W Hooper, C S Schmaljohn.   

Abstract

We have developed a rapid, reliable, and sensitive quantitative flow cytometric assay to measure the in vitro potency and stability of DNA vaccines to be delivered either by particle-mediated epidermal delivery (PMED) or by electroporation. The method involves transfecting cells with test DNA and comparing the measured antigen expression to that generated with expression from known quantities of reference material DNA. The assay was adapted for performance under Good Laboratory Practice (GLP) guidelines and was successfully utilized to perform potency testing in support of a Phase I study for two hantavirus DNA vaccines delivered by gene gun. The results from the potency assays conducted over a 24-month period using this method proved to be highly reproducible with high signal-to-noise ratios. The assay was also adapted to assess the in vitro potency and stability of a DNA vaccine for Venezuelan equine encephalitis virus that will be delivered by electroporation. Our results indicate that this assay can be readily applied to support potency and stability testing of numerous DNA vaccines delivered by various methods, including multiagent vaccines. Published by Elsevier Ltd.

Mesh:

Substances:

Year:  2011        PMID: 21219978     DOI: 10.1016/j.vaccine.2010.12.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge.

Authors:  Rebecca J Grant-Klein; Nicole M Van Deusen; Catherine V Badger; Drew Hannaman; Lesley C Dupuy; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

Review 2.  Considerations for bioanalytical characterization and batch release of COVID-19 vaccines.

Authors:  Gautam Sanyal; Anna Särnefält; Arun Kumar
Journal:  NPJ Vaccines       Date:  2021-04-13       Impact factor: 7.344

Review 3.  Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.

Authors:  James A Williams
Journal:  Vaccines (Basel)       Date:  2013-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.